Sphere Fluidics has been nominated as a Finalist in the UK Business Angel Association 2015 Angel Investment Award for “Best Investment – High Growth Manufacturing”. “We already have over 140 customers for our UK-manufactured consumable products” said Dr Frank F. Craig (CEO). “We recently closed a £1.8 million angel investment round to help us now develop high value instrumentation systems, such as Cyto-Mine – our novel high-throughput single cell analysis system. Via market research we have identified over 2,000 potential users of this product. We are now manufacturing our first Cyto-Mines.” Event info can be found here.
Dr Frank F. Craig (CEO) will be speaking on application of Sphere Fluidics’ ESI-Mine platform for Synthetic Biology at the Centre for Excellence in Biopharmaceuticals symposium on 1st July at the University of Manchester (UK). “ESI-Mine is our new platform that enables high-throughput, miniaturised screening using mass spectrometry. We can do around 200,000 samples day (c.f. 1-10,000 by normal techniques). This platform has immense potential to transform synthetic biology and metabolomic studies”. Conference information can be found here.
Dr Xin Li (Group Leader, Chemistry) will be attending and exhibiting at the Manchester University kick-off event for its Synthetic Biology Research Centre on 11th-12th June 2015. “Scientists at Manchester University are leading-edge and are interested in using Sphere Fluidics’ technology for Synthetic Biology Studies”, said Dr Li. “I will be exhibiting and providing new information on our Cyto-Mine and ESI-Mine platforms and will also present a technology overview at the conference. It will be exciting to see what the scientists discover using our new systems”.
Sphere Fluidics Limited is currently collaborating with Imperial College London on a project to screen Synthetic Biology libraries by electrospray ionisation mass spectrometry (ESI-MS). Dr Clive Smith (Principal Scientist, Sphere Fluidics) and Dr Carlos Bricio (Imperial College London) will be jointly presenting a poster entitled, “High-throughput picodroplet-based analysis of biosynthetic libraries”, at The SEED Conference in Boston (USA) on June 10th -12th, 2015. ”I am very excited to be able to present our novel high throughput screening approach at this prestigious conference and hope we can generate some excitement about our work”, said Dr Clive Smith. Conference programme can be found here.
Dr Rob Marchmont (Commercial Director) and Dr Marian Rehak (R&D Director) will be attending BIO2015, the world’s largest LIfe Sciences biopartnering conference, between June 16th – 18th, 2015. “We will also be exhibiting at the UK Pavilion, Booth number 1127. So interested companies would be welcome to drop by for updates on our new developments”, said Dr Marchmont. “I am looking forward to the biopartnering meetings we have set-up with interested potential customers and technology organisations with an interest in our emerging Cyto-Mine and ESI-Mine platforms”, said Dr Rehak. “It should be a very enjoyable and productive conference”. The conference will be held in Philadelphia (USA) and information is shown here.
Dr Frank F. Craig (CEO) will be presenting at a VIB conference titled “Next Generation Antibodies and Protein Analysis: Tools and Technologies” to be held in Ghent, Belgium on 15th-16th June, 2015. The title of his presentation will be “The Cyto-Mine Single Cell Analysis Platform for Accelerated Biopharmaceutical Discovery and Development”. “I am very honoured to be asked to speak in front of such a prestigious international audience”, he said. “VIB are a world-class, research institution and they have organised an excellent conference which covers exciting scientific areas”. Conference information can be found here.
Sphere Fluidics has just filed a UK patent on the emerging Cyto-Mine system, that will perform high-throughput, novel single cell assays, and associated Cyto-Cartridge designs. “The latter are complex, biochip structures that will enable unique single cell, cell-cell assays and improved monoclonality for biopharmaceutical discovery and development”, said Dr Marian Rehak (R&D Director). “This filing is a key patent that emphasises our strategy of protecting important elements of our single cell analysis systems”, said Dr Frank F. Craig (CEO). “We now have 12 patent families in our portfolio, many of them invented by the Sphere Fluidics’ R&D team”.